vTv Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by vTv Therapeutics Inc. (NASDAQ: VTVT) on March 3, 2022, covering events occurring on February 27, 2022, and March 1, 2022. The filing details significant executive leadership transitions and corporate governance amendments.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and corporate bylaw changes.
Material Changes and Executive Transitions
- Resignation of CEO: Ms. Deepa Prasad resigned as Chief Executive Officer, President, and Board member, effective March 29, 2022. She will serve as a Strategic Advisor for six months post-departure.
- Compensation for Departing CEO: Ms. Prasad will receive a $325,000 bonus, 15 months of base salary, and will retain 624,659 stock options vesting at the end of the 15-month period.
- Appointment of Interim CEO: Mr. Richard S. Nelson was appointed Acting CEO on March 1, 2022, transitioning to Interim CEO on March 29, 2022. Mr. Nelson is a current Board member with extensive M&A experience.
- Compensation for Interim CEO: Mr. Nelson's agreement includes a base salary of at least $200,000, a potential 100% cash bonus, and an option grant for 500,000 shares at $0.8060 per share (125,000 vesting immediately, remainder over three years).
- Bylaw Amendments: The Board adopted Second Amended and Restated By-laws to allow for the appointment of a Lead Independent Director.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of market risks. The primary contingency noted is the transition period for leadership until March 29, 2022, or the completion of a certain Company milestone, whichever occurs earlier.
Key Facts for Investor Verification
- Verify the specific "Company milestone" referenced in Ms. Prasad's resignation agreement that could accelerate her departure.
- Confirm the total equity dilution impact of the 500,000 options granted to Mr. Nelson and the 624,659 options retained by Ms. Prasad.
- Review the full text of the Second Amended and Restated By-laws (Exhibit 3.1) for details on the Lead Independent Director role.
- Monitor subsequent filings for the appointment of a permanent CEO following Mr. Nelson's interim tenure.